NEW YORK, Oct. 4, 2018 /PRNewswire/ — miR Scientific, LLC formerly known as miR Diagnostics (miR or the Company), a precision molecular bioscience company, today announces that Martin Tenniswood, Ph.D., Chief Scientific Officer presented at the 2018 World Urological Oncology Federation Conference to be held in Seoul, Korea on October 4, 2018 at 12:10PM Korea Time.
“miR Scientific is very pleased to have presented and sponsored this renowned congregation of urological leadership,” said Sam Salman, Chief Executive Officer of miR Scientific. “We believe strongly in collaborating with the oncologists and urologists who are on the frontline of cancer treatment. We look forward to presenting the results of our latest research and having meaningful discussions about the latest breakthroughs on emerging biomarkers, with the aim of disrupting legacy diagnostic methodologies to rapidly and effectively improve urogenital cancer treatment.”
Presentation Time: 12:10PM Korea Time, October 4, 2018
Presentation Title: Urinary Micro RNAs and SNOs as a Prostate Cancer Biomarker Platform
Location: Seoul Dragon City
The World Urological Oncology Federation was formed by the global leadership of 19 societies of Urologic Oncology whose shared purpose is to provide a formal integration of members to address challenges facing worldwide oncology communities. Laurence Klotz, M.D., FRCSC,CM, Chief Medical Officer of miR Scientific also serves as the conference chairman.
About miR Scientific, LLC
A subsidiary of NRS Health and Wellness GP LLC, miR Scientific is a precision molecular bioscience company that creates and delivers scalable breakthrough technologies for the provision of accessible diagnostic, prognostic, monitoring and companion products and services for large at-risk cancer populations. miR’s pipeline of products includes the Prostate Cancer Sentinel Assay Test™, a urine-based liquid biopsy test with unprecedented accuracy that has the potential to save thousands of men from suffering possible severe side effects of unnecessary prostate cancer treatments. The Company was founded in 2014 as a commercial spin-out from the State of New York University at Albany’s Cancer Research Center and currently has operations in Rensselaer, New York City, Israel and Canada. For more information, visit www.mirscientific.com.
This press release contains forward-looking statements, including with respect to the clinical development and prospects for commercialization of the Company’s product candidates, the impact and potential of the Company’s technology, and the expansion of the Company’s platform. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including delays or complications in clinical trials and attainment of regulatory approvals. The events and circumstances discussed in such forward-looking statements may not occur, and the Company’s actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this press release and are based on information available to the Company as of the date of this release.